RecruitingPhase 1NCT06875063

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Studying Hodgkin lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First Affiliated Hospital of Xiamen University
Principal Investigator
Bing Xu
The First Aiffiliated hosptical of xiamen University
Intervention
GB5005 CART(drug)
Enrollment
45 target
Eligibility
18-70 years · All sexes
Timeline
2026 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06875063 on ClinicalTrials.gov

Other trials for Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Hodgkin lymphoma →

← Back to all trials